SARS-CoV-2-specific immune responses after two versus three doses COVID-19 vaccination in end-stage renal disease patients and kidney transplant recipients

Phase 4

Completed

• Conditions: COVID-19; renal transplant, immunogenicity, safety, humoral immunity, cell-mediated immunity

• Registration Number: TCTR20210524002
• Lead Sponsor: Faculty of Medicine Ramathibodi Hospital, Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-24
• Study Completion: 2021-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

All adult ESRD, either HD or PD, and kidney transplant recipients

Exclusion Criteria

Active infection
Allograft rejection
Previous COVID-19 infection
Receiving COVID-19 vaccine prior to including in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immunogenicity 4 weeks after the last vaccine dose SARS-CoV-2 specific immune responses

Secondary Outcome Measures

Name	Time	Method
Safety 4 weeks after the last vaccine dose Adverse reactions